Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 1
2012 1
2013 3
2015 1
2016 6
2017 5
2018 5
2019 9
2020 8
2021 11
2022 9
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease: A Nationwide, Multicenter Cohort Study.
Tison A, Quéré G, Misery L, Funck-Brentano E, Danlos FX, Routier E, Robert C, Loriot Y, Lambotte O, Bonniaud B, Scalbert C, Maanaoui S, Lesimple T, Martinez S, Marcq M, Chouaid C, Dubos C, Brunet-Possenti F, Stavris C, Chiche L, Beneton N, Mansard S, Guisier F, Doubre H, Skowron F, Aubin F, Zehou O, Roge C, Lambert M, Pham-Ledard A, Beylot-Barry M, Veillon R, Kramkimel N, Giacchero D, De Quatrebarbes J, Michel C, Auliac JB, Gonzales G, Decroisette C, Le Garff G, Carpiuc I, Vallerand H, Nowak E, Cornec D, Kostine M; Groupe de Cancérologie Cutanée, Groupe Français de Pneumo-Cancérologie, and Club Rhumatismes et Inflammations. Tison A, et al. Among authors: brunet possenti f. Arthritis Rheumatol. 2019 Dec;71(12):2100-2111. doi: 10.1002/art.41068. Epub 2019 Oct 21. Arthritis Rheumatol. 2019. PMID: 31379105
Immune checkpoint inhibitors-related orchitis.
Brunet-Possenti F, Opsomer MA, Gomez L, Ouzaid I, Descamps V. Brunet-Possenti F, et al. Ann Oncol. 2017 Apr 1;28(4):906-907. doi: 10.1093/annonc/mdw696. Ann Oncol. 2017. PMID: 28039179 Free article. No abstract available.
Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Nardin C, Hennemann A, Diallo K, Funck-Brentano E, Puzenat E, Heidelberger V, Jeudy G, Samimi M, Lesage C, Boussemart L, Peuvrel L, Rouanet J, Brunet-Possenti F, Gerard E, Seris A, Jouary T, Saint-Jean M, Puyraveau M, Saiag P, Aubin F. Nardin C, et al. Among authors: brunet possenti f. Cancers (Basel). 2023 Jul 10;15(14):3564. doi: 10.3390/cancers15143564. Cancers (Basel). 2023. PMID: 37509227 Free PMC article.
Successful rechallenge with avelumab in Merkel cell carcinoma.
Amiot M, Brunet Possenti F, Lebbé C, Baroudjian B. Amiot M, et al. Among authors: brunet possenti f. Eur J Cancer. 2021 Aug;153:96-97. doi: 10.1016/j.ejca.2021.05.024. Epub 2021 Jun 18. Eur J Cancer. 2021. PMID: 34153719 No abstract available.
Genital Pseudotumor as a Manifestation of Mpox Virus Infection.
Blanchet FX, Rahi M, Merlant M, Gare M, Brunet-Possenti F, Descamps V, Bouscarat F. Blanchet FX, et al. Among authors: brunet possenti f. JAMA Dermatol. 2023 May 1;159(5):563-564. doi: 10.1001/jamadermatol.2023.0307. JAMA Dermatol. 2023. PMID: 36947032
Safe use of tocilizumab in rheumatic patients with Kaposi's sarcoma.
Demouche S, Juge PA, Charles P, Descamps V, Benali K, Brunet-Possenti F. Demouche S, et al. Among authors: brunet possenti f. Dermatol Ther. 2022 Nov;35(11):e15797. doi: 10.1111/dth.15797. Epub 2022 Sep 13. Dermatol Ther. 2022. PMID: 36038806 Free PMC article. No abstract available.
Combined Nivolumab and Ipilimumab in Octogenarian and Nonagenarian Melanoma Patients.
Reichert C, Baldini C, Mezghani S, Maubec E, Longvert C, Mortier L, Quereux G, Jannic A, Machet L, de Quatrebarbes J, Nardin C, Beneton N, Amini Adle M, Funck-Brentano E, Descamps V, Hachon L, Malissen N, Baroudjian B, Brunet-Possenti F; Groupe de Cancérologie Cutanée. Reichert C, et al. Among authors: brunet possenti f. Cancers (Basel). 2023 Aug 30;15(17):4330. doi: 10.3390/cancers15174330. Cancers (Basel). 2023. PMID: 37686606 Free PMC article.
Pneumocystosis revealing immunodeficiency secondary to TERC mutation.
Borie R, Kannengiesser C, Sicre de Fontbrune F, Boutboul D, Tabeze L, Brunet-Possenti F, Lainey E, Debray MP, Cazes A, Crestani B. Borie R, et al. Among authors: brunet possenti f. Eur Respir J. 2017 Nov 22;50(5):1701443. doi: 10.1183/13993003.01443-2017. Print 2017 Nov. Eur Respir J. 2017. PMID: 29167304 Free article. No abstract available.
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in France.
Kandel M, Bardet A, Dalle S, Allayous C, Mortier L, Guillot B, Dutriaux C, Leccia MT, Dalac S, Montaudie H, Saiag P, Legoupil D, Brunet-Possenti F, Arnault JP, Quatrebarbes J, Beylot-Barry M, Maubec E, Lesimple T, Aubin F, Grob JJ, Granel-Brocard F, Stoebner PE, Dupuy A, Dreno B, Michiels S, Lebbe C, Borget I. Kandel M, et al. Among authors: brunet possenti f. Curr Oncol. 2022 Nov 27;29(12):9255-9270. doi: 10.3390/curroncol29120725. Curr Oncol. 2022. PMID: 36547139 Free PMC article.
58 results